{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:11:02Z","timestamp":1789726262468,"version":"4.0.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,3,2]],"date-time":"2007-03-02T00:00:00Z","timestamp":1172793600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Delivery of tobramycin by inhalation to the lungs of patients with cystic fibrosis (CF) who are infected with <jats:italic>Pseudomonas aeruginosa<\/jats:italic> has been proven to be effective and safe. The aerosol administration allows high concentrations of tobramycin to be delivered to the site of infection with limited systemic absorption. In rare patients, systemic absorption of inhaled tobramycin may be significant enough to produce toxic effects, such as renal and vestibular toxicities.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative-free tobramycin by inhalation, beginning at 16 months of age. Also, he developed similar signs and symptoms when he was administered tobramycin intravenously on one occasion at 5 1\/2 years. The patient had a history of environmental allergies. Temporal sequence of his signs and symptoms after each administration of tobramycin (similar to re-challenge testing), and his improvement after discontinuation of the drug strongly suggest an adverse drug reaction.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2431-7-11","type":"journal-article","created":{"date-parts":[[2007,3,2]],"date-time":"2007-03-02T08:27:41Z","timestamp":1172824061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report"],"prefix":"10.1186","volume":"7","author":[{"given":"Roberto P","family":"Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Awa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran D","family":"Anbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,3,2]]},"reference":[{"issue":"6","key":"147_CR1","doi-asserted-by":"publisher","first-page":"E89","DOI":"10.1542\/peds.106.6.e89","volume":"106","author":"CG Prober","year":"2000","unstructured":"Prober CG, Walson PD, Jones J, Committee on Infectious Diseases and Committee on Drugs: Technical report: precautions regarding the use of aerosolized antibiotics. Pediatrics. 2000, 106 (6): E89-10.1542\/peds.106.6.e89.","journal-title":"Pediatrics"},{"issue":"3","key":"147_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/j.1552-4604.1994.tb03995.x","volume":"34","author":"GF Cooney","year":"1994","unstructured":"Cooney GF, Lum BL, Tomaselli M, Fiel SB: Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J Clin Pharmacol. 1994, 34 (3): 255-259.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"147_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/ppul.10185","volume":"34","author":"IM Hoffmann","year":"2002","unstructured":"Hoffmann IM, Rubin BK, Iskandar SS, Schechter MS, Nagaraj SK, Bitzan MM: Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Pediatr Pulmonol. 2002, 34 (5): 375-377. 10.1002\/ppul.10185.","journal-title":"Pediatr Pulmonol"},{"issue":"9","key":"147_CR4","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/S0025-6196(11)62603-7","volume":"79","author":"RS Edson","year":"2004","unstructured":"Edson RS, Brey RH, McDonald TJ, Terrell CL, McCarthy JT, Thibert JM: Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency. Mayo Clin Proc. 2004, 79 (9): 1185-1191.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"147_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/ppul.10049","volume":"33","author":"MG Spigarelli","year":"2002","unstructured":"Spigarelli MG, Hurwitz ME, Nasr SZ: Hypersenstivity to inhaled TOBI\u00ae following reaction to gentamicin. Pediatr Pulmonol. 2002, 33 (4): 311-314. 10.1002\/ppul.10049.","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"147_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJM199901073400104","volume":"340","author":"BW Ramsey","year":"1999","unstructured":"Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999, 340 (1): 23-30. 10.1056\/NEJM199901073400104.","journal-title":"N Engl J Med"},{"issue":"6","key":"147_CR7","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1164\/rccm.200208-855OC","volume":"167","author":"RL Gibson","year":"2003","unstructured":"Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B, Cystic Fibrosis Therapeutics Development Network Study Group: Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med. 2003, 167 (6): 841-849. 10.1164\/rccm.200208-855OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3 Pt 2 Suppl","key":"147_CR8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.5694\/j.1326-5377.1977.tb113918.x","volume":"2","author":"BR Meyers","year":"1977","unstructured":"Meyers BR: Clinical study of the use of the new aminoglycoside tobramycin for therapy of infections due to gram-negative bacteria. Med J Aust. 1977, 2 (3 Pt 2 Suppl): 38-40.","journal-title":"Med J Aust"},{"issue":"7","key":"147_CR9","first-page":"358","volume":"50","author":"LM Jones","year":"1984","unstructured":"Jones LM, Miller S: Bacterial peritonitis. Protecting the high-risk patient. Am Surg. 1984, 50 (7): 358-361.","journal-title":"Am Surg"},{"issue":"6","key":"147_CR10","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1097\/00007611-199006000-00035","volume":"83","author":"BA Hannah","year":"1990","unstructured":"Hannah BA, Kimmel PL, Dosa S, Turner ML: Vancomycin-induced toxic epidermal necrolysis. South Med J. 1990, 83 (6): 720-722. 10.1097\/00007611-199006000-00035.","journal-title":"South Med J"},{"issue":"9237","key":"147_CR11","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK: Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000, 356 (9237): 1255-1259. 10.1016\/S0140-6736(00)02799-9.","journal-title":"Lancet"},{"issue":"2","key":"147_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30 (2): 239-245.","journal-title":"Clin Pharmacol Ther"},{"issue":"7\u20138","key":"147_CR13","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1177\/106002809502907-810","volume":"29","author":"JS Schretlen-Doherty","year":"1995","unstructured":"Schretlen-Doherty JS, Troutman WG: Tobramycin-induced hypersensitivity reaction. Ann Pharmacother. 1995, 29 (7\u20138): 704-706.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"147_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/jac\/41.2.215","volume":"41","author":"LB Quesnel","year":"1998","unstructured":"Quesnel LB, Jaran AS, Braganza JM: Antibiotic accumulation and membrane trafficking in cystic fibrosis cells. J Antimicrob Chemother. 1998, 41 (2): 215-221. 10.1093\/jac\/41.2.215.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"147_CR15","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/thx.2004.027953","volume":"60","author":"JS Parmar","year":"2005","unstructured":"Parmar JS, Nasser S: Antibiotic allergy in cystic fibrosis. Thorax. 2005, 60 (6): 517-520. 10.1136\/thx.2004.027953.","journal-title":"Thorax"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2431-7-11.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2431-7-11\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2431-7-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2431-7-11.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T22:55:43Z","timestamp":1630450543000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/1471-2431-7-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,2]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["147"],"URL":"https:\/\/doi.org\/10.1186\/1471-2431-7-11","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,2]]},"assertion":[{"value":"23 August 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"11"}}